Vigil Neuroscience Inc
VIGL8.055USD
+0.005+0.06%
Horário de mercado （ET）Cotações atrasadas em 15 min
375.94MValor de mercado
PerdaP/L TTM
Mais detalhes de Vigil Neuroscience Inc Empresa
Vigil Neuroscience, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Its lead clinical candidate, VGL101 (iluzanebart), is a fully human monoclonal antibody TREM2 agonist that is being studied in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. The Company is also developing VG-3927, its orally available small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease in genetically defined subpopulations.
Informações da empresa
Código da empresaVIGL
Nome da EmpresaVigil Neuroscience Inc
Data de listagemJan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Número de funcionários69
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 07
Endereço100 Forge Road
CidadeWATERTOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02472
Telefone18572544445
Sitehttps://www.vigilneuro.com/
Código da empresaVIGL
Data de listagemJan 07, 2022
CEODr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. David Gray, Ph.D.
Dr. David Gray, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Gerhard Koenig, Ph.D.
Dr. Gerhard Koenig, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Ziolkowski, CPA
Ms. Jennifer Ziolkowski, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stefan Vitorovic
Mr. Stefan Vitorovic
Independent Director
Independent Director
--
-100.00%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Samantha Budd Haeberlein, Ph.D.
Dr. Samantha Budd Haeberlein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Dr. Cheryl Renee Blanchard, Ph.D.
Dr. Cheryl Renee Blanchard, Ph.D.
Independent Director
Independent Director
--
--
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Dr. Suzanne Louise (Sue) Bruhn, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
Dr. Ivana Magovcevic-Liebisch, J.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Petra Kaufmann, M.D.
Ms. Petra Kaufmann, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 1 de ago
Atualizado em: sex, 1 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
Investidores
Investidores
Proporção
Atlas Venture
12.51%
Beryl Capital Management, LLC
9.87%
BVF Partners L.P.
8.60%
Amgen Inc
6.87%
Glazer Capital, LLC
5.39%
Other
56.77%
Tipos de investidores
Investidores
Proporção
Hedge Fund
33.86%
Venture Capital
17.21%
Investment Advisor
11.63%
Corporation
6.87%
Investment Advisor/Hedge Fund
3.73%
Individual Investor
0.51%
Research Firm
0.40%
Bank and Trust
0.17%
Other
25.62%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
167
34.72M
74.40%
-8.46M
2025Q1
155
37.71M
83.92%
-8.48M
2024Q4
145
40.31M
98.61%
+1.04M
2024Q3
142
37.92M
96.31%
-1.37M
2024Q2
139
36.35M
96.29%
-1.95M
2024Q1
131
36.78M
100.64%
+157.59K
2023Q4
124
35.04M
97.83%
-1.22M
2023Q3
117
35.82M
100.15%
-590.79K
2023Q2
111
36.00M
101.04%
+568.49K
2023Q1
103
35.28M
105.30%
-113.43K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Atlas Venture
5.84M
12.51%
--
--
Jun 11, 2025
Beryl Capital Management, LLC
4.61M
9.87%
+4.61M
--
May 22, 2025
BVF Partners L.P.
4.01M
8.6%
+2.20M
+121.30%
Mar 31, 2025
Amgen Inc
3.21M
6.87%
--
--
Jun 11, 2025
Glazer Capital, LLC
2.51M
5.39%
+2.51M
--
May 28, 2025
Invus Public Equities Advisors, LLC
1.97M
4.21%
-23.97K
-1.20%
Mar 31, 2025
683 Capital Management LLC
1.74M
3.73%
+340.00K
+24.29%
Mar 31, 2025
VV Manager LLC
1.63M
3.5%
-3.38M
-67.41%
Jun 11, 2025
Sphera Funds Management Ltd.
1.60M
3.44%
+102.00K
+6.79%
Mar 31, 2025
Ensign Peak Advisors, Inc.
1.58M
3.38%
+875.00K
+124.45%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
NYLI Merger Arbitrage ETF
0.2%
iShares Health Innovation Active ETF
0.1%
iShares Micro-Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Ver Mais
NYLI Merger Arbitrage ETF
Proporção0.2%
iShares Health Innovation Active ETF
Proporção0.1%
iShares Micro-Cap ETF
Proporção0.05%
Avantis US Small Cap Equity ETF
Proporção0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Global X Russell 2000 ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
